IP Library Granted Patent US 9,046,529
Granted Patent B2
US 9,046,529 · App. 13/262,752 · Granted Jun 2, 2015

Prostatitis-associated antigens and methods of use thereof

Inventors: Lawrence H. Fong (Palo Alto, CA); Yafei Hou (Mountain View, CA); Jason J. Devoss (San Francisco, CA); Mark Stuart Anderson (Larkspur, CA)
Assignee: The Regents of the University of California
G01N33/6893A61K39/00C07K14/47G01N2800/342
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,046,529
App. No.
13/262,752
Granted
Jun 2, 2015
Kind
B2
Abstract

The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia.

Claims (8)

1. A method of diagnosing an individual as having prostatitis, the method comprising:

assaying the level of T cells specific for a human semenogelin polypeptide in a biological sample obtained from the individual;

identifying the individual as having prostatitis when the level of T cells specific for the human semenogelin polypeptide is greater than a normal control level; and

outputting a report indicating the level of T cells specific for the human semenogelin polypeptide.

2. The method of claim 1 , wherein said biological sample is serum, blood, plasma, or seminal fluid.

3. The method of claim 1 , wherein said individual is a human male.

4. The method of claim 1 , wherein said individual has a higher than normal level of prostate-specific antigen.

5. The method of claim 1 , further comprising assaying the level of prostate specific antigen (PSA) in the biological sample, wherein the level of PSA provides for diagnosis of prostate cancer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 23, 2015
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036014/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2011
From: FONG, LAWRENCE H.; HOU, YAFEI; DEVOSS, JASON J.; ANDERSON, MARK STUART
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 027179/0296 →
Continuity (2)
Provisional Application 61168506 · Apr 10, 2009
Related Publication 20120093820A1 · Apr 19, 2012